News
Home | News
WuXi AppTec Breaks Ground on New Site in Singapore to Better Support Global Customers
May 23, 2024Photo caption (from left to right): Ms. Cindy Koh, Executive Vice President, Singapore Economic Development Board; Dr. Minzhang Chen, Co-CEO, WuXi AppTec; Mr. Heng Swee Keat, Deputy Prime Minister; Dr. Ge Li,…
A Successful PAI for a new Peptide Drug from Japan PMDA
April 9, 2024Our peptide manufacturing facility at Changzhou site has successfully passed the Pre-Approval Inspection by Japan Pharmaceuticals and Medical Devices Agency (PMDA) for an innovative peptide drug. The 3-day inspection, without any major…
2024 CDMO Leadership Awards
March 21, 2024Exciting moment! We’ve been honored with the 2024 CDMO Leadership Awards in all six core categories: Capabilities, Compatibility, Expertise, Quality, Reliability, and Service, again! Dr. Jinling Chen, our Senior Vice President and…
WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing API Manufacturing Site
January 8, 2024Expansion Boosts Solid-Phase Peptide Synthesis Total Reactor Volume to 32,000 Liters in Response to Surging Demand Shanghai, China – January 8, 2024 — WuXi AppTec, a global company that provides a broad…
WuXi STA Debuts Its First High Potency Sterile Injectable Manufacturing Line at Wuxi City Site
July 17, 2023Shanghai, China, July 17, 2023 -- WuXi STA, a global Contract Research, Development, and Manufacturing Organization (CRDMO), today launched its first high potency (HP), fully automated sterile injectable manufacturing line at the…
WuXi STA Forms Strategic Partnership with Ark Biopharmaceutical for the Commercial Supply of Ziresovir
May 23, 2023SHANGHAI, CHINA, May 23, 2023 - WuXi STA, a subsidiary of WuXi AppTec, and Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced a strategic partnership for the commercial supply of ziresovir, a novel…
